Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05456841
Other study ID # 21-339
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 28, 2023
Est. completion date August 31, 2026

Study information

Verified date May 2024
Source Memorial Sloan Kettering Cancer Center
Contact Smita Banerjee, PhD
Phone 646-888-0011
Email banerjes@mskcc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Research indicates that perceived stigma within medical encounters is prevalent and problematic for lung cancer patients' well-being and quality of cancer care. Promoting empathic communication appears to be a potentially effective intervention target to help reduce patients' perceptions of stigma within clinical encounters; however, no formal trainings exist that focus on teaching empathic communication to oncology care providers (OCPs). Building upon favorable findings from a prior R21 (R21CA202793) and the importance of developing interventions to address lung cancer stigma, our goal is to conduct a national trial of empathic communication skills (ECS) training to facilitate improvements in the medical and psychosocial care of patients through de-stigmatizing interactions with OCPs for patients diagnosed with lung cancer.


Description:

The aims of this study are: 1. to evaluate the effect of the ECS training on OCP primary outcomes (communication and empathic skill uptake) and secondary outcomes (ECS training appraisal - relevance, novelty, clarity; self-efficacy, empathy, compassion burn-out); 2. to evaluate the effect of the ECS training vs. WLC on patients' reported primary outcomes (lung cancer stigma), and secondary outcomes (perceived clinician empathy, satisfaction with communication, psychological distress, patients' experience of clinical encounter, and overall patient satisfaction). Additionally, acceptance of referral to tobacco cessation (for those currently smoking) will be explored; and 3. to examine potential moderators of OCP (e.g., demographic characteristics, professional role characteristics) and patient outcomes (e.g., demographic characteristics, illness characteristics). Our central hypothesis is that the ECS training will demonstrate significant short-term improvements in clinicians' uptake of empathic skills and self-efficacy and will be superior to WLC with regards to patient reported measures of stigma, clinician empathy, satisfaction, and overall experience.


Recruitment information / eligibility

Status Recruiting
Enrollment 1232
Est. completion date August 31, 2026
Est. primary completion date September 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: Site Eligibility - Employs at least 15 FTE OCPs (i.e., oncologists, nurse practitioners and physician assistants) as per self report - Reports a clinic volume of at least 20 new lung cancer patients per month as per self report OCP Participant Eligibility - OCPs who are thoracic oncology physicians (radiologists, medical oncologists, pulmonologists, and surgeons), NPs, or PAs and currently treating lung cancer patients, as per self-report; - OCP conducts consultations with lung cancer patients, as per self-report; - OCP sees at least 1 lung cancer patient per week, as per self-report; Patient Eligibility - Patient under the care of a participating OCP as per self report; - English and/or Spanish speaking; - In general, which language do you prefer to receive your medical care, English/Spanish/both English and Spanish Equally? - If English, treat as fluent in English, no additional language questions - If Spanish, treat as fluent in Spanish, no additional language questions - If both English and Spanish equally, ask the follow-up questions and go with whichever language is endorsed as best. If endorsed equally, assign to category patient prefers - How well do you speak English? Not at all/ Not well/Well/Very well - How well do you speak Spanish? Not at all/Not well/Well/Very well - Is at least 18 years of age as per self report; - Has a history of suspicious lung mass or confirmed lung cancer diagnosis, as per clinician judgment or medical record note; - Is a former or current smoking as per self report; - Has had no more than 10 prior visits with the participating OCP, as per the medical record and/or self report Exclusion Criteria: Patient Exclusion - Individuals of impaired decision-making capacity as per a clinician's judgment or as documented in the EMR. Site and OCP Exclusion - None

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Empathic Communication Skills (ECS) training
The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given "small doses" of an opposing viewpoint (termed as "preparing patients for recurring smoking questions") and suggestions of "counterarguments" in order to make them resistant to future stigmatizing attacks by others
Other:
Standard of Care participant interaction
Standard of Care participant interaction

Locations

Country Name City State
United States Chesapeake Regional Healthcare (Data Collection Only) Chesapeake Virginia
United States Hackensack Meridian Health (Data collection only) Hackensack New Jersey
United States Providence St. Joseph Health (Data Collection Only) Irvine California
United States University of Kentucky (Data Collection Only) Lexington Kentucky
United States Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York
United States Virtua Health (Data Collection Only) Philadelphia Pennsylvania
United States Munson Healthcare (Data Collection Only) Traverse City Michigan

Sponsors (3)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center American Cancer Society, Inc., Go2 Foundation for Lung Cancer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Uptake of communication skills using standardized patient assessment/SPAs A SPA involves a 12-minute video recorded interaction between the Oncology Care Provider/OCP and the Standardized Patient/SP on a given clinical scenario, using standardized scripts by the SP. Each OCP will participate in one SPA prior to their ECS training and one SPA following training or the timed control period. In contrast to clinical consultation recordings with varied clinical situations that do not necessitate the use of all strategies and skills, the semi-structured nature of SPAs permits appraisal of all desired elements of training. 3 months
Primary Uptake of empathy skills using standardized patient assessment/SPAs A SPA involves a 12-minute video recorded interaction between the Oncology Care Provider/OCP and the Standardized Patient/SP on a given clinical scenario, using standardized scripts by the SP. Each OCP will participate in one SPA prior to their ECS training and one SPA following training or the timed control period. In contrast to clinical consultation recordings with varied clinical situations that do not necessitate the use of all strategies and skills, the semi-structured nature of SPAs permits appraisal of all desired elements of training. 3 months
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk